Takeda Pharmaceutical (TAK) Debt to Equity: 2018-2025
- Takeda Pharmaceutical's Debt to Equity fell 2.24% to $0.65 in Q1 2025 from the same period last year, while for Mar 2025 it was $0.65, marking a year-over-year decrease of 2.24%. This contributed to the annual value of $0.65 for FY2025, which is 2.24% down from last year.
- Takeda Pharmaceutical's Debt to Equity amounted to $0.65 in Q1 2025, which was down 2.24% from $0.67 recorded in Q1 2024.
- Over the past 5 years, Takeda Pharmaceutical's Debt to Equity peaked at $0.94 during Q1 2021, and registered a low of $0.65 during Q1 2025.
- In the last 3 years, Takeda Pharmaceutical's Debt to Equity had a median value of $0.67 in 2024 and averaged $0.67.
- Data for Takeda Pharmaceutical's Debt to Equity shows a maximum YoY fell of 18.61% (in 2022) over the last 5 years.
- Quarterly analysis of 5 years shows Takeda Pharmaceutical's Debt to Equity stood at $0.94 in 2021, then dropped by 18.61% to $0.76 in 2022, then dropped by 9.77% to $0.69 in 2023, then declined by 3.44% to $0.67 in 2024, then dropped by 2.24% to $0.65 in 2025.
- Its last three reported values are $0.65 in Q1 2025, $0.67 for Q1 2024, and $0.69 during Q1 2023.
